Neurologic Disorders Therapeutics

Global Neurologic Disorders Therapeutics Market to Reach US$136.9 Billion by 2032

The global market for Neurologic Disorders Therapeutics estimated at US$102.6 Billion in the year 2025, is expected to reach US$136.9 Billion by 2032, growing at a CAGR of 4.2% over the analysis period 2025-2032. Anticholinergic Drug Class, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$41.5 Billion by the end of the analysis period. Growth in the Analgesics Drug Class segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.7 Billion While China is Forecast to Grow at 7.7% CAGR

The Neurologic Disorders Therapeutics market in the U.S. is estimated at US$31.7 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$33.0 Billion by the year 2032 trailing a CAGR of 7.7% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Neurologic Disorders Therapeutics Market - Key Drivers and Trends Summarized

Neurologic disorders encompass a broad range of conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. These disorders can be debilitating and include diseases such as Alzheimer`s, Parkinson`s, multiple sclerosis, epilepsy, and stroke, among others. The therapeutic approaches for neurologic disorders vary widely depending on the specific condition, but generally aim to manage symptoms, slow disease progression, and improve the quality of life for patients. Treatments can include medications, physical and occupational therapy, lifestyle changes, and, in some cases, surgical interventions.

The field of neurologic disorder therapeutics has seen significant advancements over the past few decades. The development of disease-modifying therapies has transformed the management of conditions like multiple sclerosis and Parkinson`s disease, offering patients options that go beyond symptomatic relief. For instance, the introduction of monoclonal antibodies and other biologic drugs has provided new avenues for targeting the underlying pathophysiology of these diseases. Advances in neuroimaging and biomarker research have also enhanced early diagnosis and personalized treatment plans. Moreover, innovative drug delivery systems, such as intrathecal pumps and transdermal patches, have improved the efficacy and convenience of administering neurologic medications.

The growth in the neurologic disorders therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurologic conditions, particularly among aging populations, has heightened the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceutical research are continuously leading to the development of new and improved therapies, including gene therapies and neuroprotective agents. The expansion of healthcare infrastructure in emerging markets has also facilitated better access to neurologic care, contributing to market growth. Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies, including telemedicine and wearable devices, is enhancing patient monitoring and management, leading to better outcomes. Lastly, increased funding for neurologic research and the development of comprehensive treatment guidelines are fostering a more structured and effective approach to managing neurologic disorders.

 

SCOPE OF STUDY:

The report analyzes the Neurologic Disorders Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• AstraZeneca PLC
• Biogen, Inc.
• Biohaven, Ltd.
• Eisai Co., Ltd.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neurelis, Inc.
• Neurocrine Biosciences, Inc.
• Neurona Therapeutics, Inc.
• Ovid Therapeutics, Inc.
• Pfizer, Inc.
• Sanofi SA
• UCB SA
• Voyager Therapeutics, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more